All Eyes On Gilead
Bloomberg Businessweek|May 18, 2020
Emergency approval of the antiviral drug remdesivir is the first good news of this pandemic. Gilead Sciences was ready
By Robert Langreth
All Eyes On Gilead

LAST NEW YEAR’S EVE, TOMAS CIHLAR, VICE PRESIDENT for discovery virology at Gilead Sciences Inc., received a disturbing email from a top infectious diseases expert at the University of Virginia. The researcher had been working with Cihlar on a plan to test the Gilead drug remdesivir as a treatment for Middle East respiratory syndrome, a deadly disease caused by a coronavirus. MERS had been flaring up from time to time in Saudi Arabia and elsewhere since 2012, but this email was about something more ominous. There were cases of pneumonia suddenly emerging in Wuhan, China. Watch this one, the virologist warned. It might be a new coronavirus.

Remdesivir was one of the few experimental medicines that had shown promise in lab studies against a wide variety of coronaviruses. Like the rest of the world, Gilead knew next to nothing about this new one. The World Health Organization hadn’t yet confirmed there was sustained human-to-human spread, and the extent of the outbreak in Wuhan wouldn’t become clear for weeks. Nobody knew at that point whether it would become a pandemic, but Gilead started planning on the assumption it could. Within weeks, Chief Executive Officer Daniel O’Day formed a task force to study how to test remdesivir and, if it worked, mass-produce it.

この記事は Bloomberg Businessweek の May 18, 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

この記事は Bloomberg Businessweek の May 18, 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

BLOOMBERG BUSINESSWEEKのその他の記事すべて表示
Instagram's Founders Say It's Time for a New Social App
Bloomberg Businessweek US

Instagram's Founders Say It's Time for a New Social App

The rise of AI and the fall of Twitter could create opportunities for upstarts

time-read
4 分  |
March 13, 2023
Running in Circles
Bloomberg Businessweek US

Running in Circles

A subscription running shoe program aims to fight footwear waste

time-read
3 分  |
March 20 - 27, 2023
What I Learned Working at a Hawaiien Mega-Resort
Bloomberg Businessweek US

What I Learned Working at a Hawaiien Mega-Resort

Nine wild secrets from the staff at Turtle Bay, who have to manage everyone from haughty honeymooners to go-go-dancing golfers.

time-read
10 分  |
March 20 - 27, 2023
How Noma Will Blossom In Kyoto
Bloomberg Businessweek US

How Noma Will Blossom In Kyoto

The best restaurant in the world just began its second pop-up in Japan. Here's what's cooking

time-read
3 分  |
March 20 - 27, 2023
The Last-Mover Problem
Bloomberg Businessweek US

The Last-Mover Problem

A startup called Sennder is trying to bring an extremely tech-resistant industry into the age of apps

time-read
10+ 分  |
March 20 - 27, 2023
Tick Tock, TikTok
Bloomberg Businessweek US

Tick Tock, TikTok

The US thinks the Chinese-owned social media app is a major national security risk. TikTok is running out of ways to avoid a ban

time-read
10+ 分  |
March 20 - 27, 2023
Cleaner Clothing Dye, Made From Bacteria
Bloomberg Businessweek US

Cleaner Clothing Dye, Made From Bacteria

A UK company produces colors with less water than conventional methods and no toxic chemicals

time-read
3 分  |
March 20 - 27, 2023
Pumping Heat in Hamburg
Bloomberg Businessweek US

Pumping Heat in Hamburg

The German port city plans to store hot water underground and bring it up to heat homes in the winter

time-read
3 分  |
March 20 - 27, 2023
Sustainability: Calamari's Climate Edge
Bloomberg Businessweek US

Sustainability: Calamari's Climate Edge

Squid's ability to flourish in warmer waters makes it fitting for a diet for the changing environment

time-read
4 分  |
March 20 - 27, 2023
New Money, New Problems
Bloomberg Businessweek US

New Money, New Problems

In Naples, an influx of wealthy is displacing out-of-towners lower-income workers

time-read
4 分  |
March 20 - 27, 2023